APP and Alzheimer disease: In 3xTg-AD and APP/PS1-AD mice, ligustrazine significantly improved the learning and memory ability of these two kinds of AD transgenic mice, reduced Aβ and p-tau levels, altered the seahorse proteome and reduced AD pathology (Huang et al., 2021).